SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, BCMA

September 13, 2023

2seventy bio Announces Strategic Restructuring and Pipeline Reprioritization; Abecma’s US Revenue Guidance Lowered; Nick Leschly to Resign as CEO; Company to Expand Strategic Partnership with JW Tx

Here is a brief preview of this blast: On September 12, 2023, 2seventy bio held a conference call (webcast / press release) announcing the strategic restructuring of the company’s business operations and R&D model. Measures include a 40% workforce reduction and a pipeline reprioritization and are driven by a projected decrease in Abecma’s (BMS / 2seventy BCMA CAR-T) revenue for 2023. Additionally, the company disclosed Nick Leschly's decision to step down as CEO. On the same day, 2seventy announced the expansion of its collaboration with JW Tx adding 2 new assets from its pipeline: a solid tumor targeting TCR-T and a CAR-T for autoimmune diseases (press release). Below, Celltelligence provides insights on 2seventy’s new Abecma revenue projections for 2023 and the collaborative R&D model that the company aims to implement for its pipeline.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.